Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ora Frankel

Psychiatry Louisville, KY Medical Doctor

NPI 1700072287 CMS profile 122775

2327 Lime Kiln Ln Ste A, Louisville, KY 40222

Open in the dashboard

General payments

$6,225

386 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ora Frankel of Louisville, KY is reported in the CMS Open Payments database as having received $6,225 across 386 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $709 37
2024 General $687 47
2023 General $1,050 65
2022 General $1,314 75
2021 General $994 55
2020 General $273 25
2019 General $1,198 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ora Frankel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ora Frankel were reported at $709. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ora Frankel Psychiatry median Middle half National median
2019 $1,198 $184 $59–$605 $163
2020 $273 $119 $36–$372 $114
2021 $994 $143 $43–$576 $132
2022 $1,314 $153 $50–$590 $149
2023 $1,050 $170 $56–$651 $160
2024 $687 $179 $57–$673 $164
2025 $709 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $683 55 payments
  2. Lundbeck LLC $676 34 payments
  3. Bausch Health US, LLC $646 59 payments
  4. Otsuka America Pharmaceutical, Inc. $531 27 payments
  5. ITI, Inc. $328 14 payments
  6. Alkermes, Inc. $307 13 payments
  7. Neurocrine Biosciences, Inc. $274 16 payments
  8. Vanda Pharmaceuticals Inc. $248 10 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $237 18 payments
  10. Corium, Inc. $233 15 payments
  11. Other $2,061 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,053 383 payments
  2. Education $172 3 payments
Products named General payments · program years 2019–2025
  1. APLENZIN $646 59 payments
  2. WELLBUTRIN $628 58 payments
  3. REXULTI Psychiatry $548 25 payments
  4. VRAYLAR Neuroscience $500 45 payments
  5. REXULTI Psychiatry $438 23 payments
  6. VRAYLAR Neuroscience $355 32 payments
  7. LYBALVI Cns $307 13 payments
  8. LYBALVI Cns $307 13 payments
  9. LYBALVI Cns $287 12 payments
  10. LYBALVI Cns $287 12 payments
  11. Other $3,992 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,375

Median for Psychiatry & Neurology: 100

Drug cost

$234,627

Median for Psychiatry & Neurology: $2,986

Branded share of claims

29.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 20 $49,705
Vyvanse Lisdexamfetamine Dimesylate Brand 86 $37,918
Trintellix Vortioxetine Hydrobromide Brand 34 $33,921
Auvelity Dextromethorphan Hbr/Bupropion Brand 19 $31,743
Lisdexamfetamine Dimesylate Generic 58 $21,084
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 38 $10,589
Quviviq Daridorexant Hcl Brand 12 $7,265
Asenapine Maleate Generic 14 $5,532
Aripiprazole Generic 57 $5,386
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 33 $4,876

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $182
$182 20 —
REXULTI
  • Lundbeck LLC $92
  • Otsuka America Pharmaceutical, Inc. $17
$110 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $87
$87 — —
Xelstrym
  • Noven Therapeutics, LLC $56
$56 — —
Azstarys
  • Corium, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record